Trial Profile
A phase 2 multicenter clinical study evaluating the safety and efficacy of Nilotinib in patients with Imatinib- resistant/intolerant CML in chronic phase
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms TSSG nilotinib-study
- 10 May 2017 New trial record